Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

GH Axis Mechanism Map

A high-level map of growth-hormone-axis signalling and where the GH-axis peptides on this site interact with it. Includes pathway background, the receptor targets that matter, and an honest read of where human evidence sits.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Pathway background

The hypothalamic-pituitary-GH axis is the master regulator of postnatal growth and a major contributor to metabolic regulation in adulthood. Hypothalamic neurons in the arcuate nucleus secrete growth-hormone-releasing hormone (GHRH) into the portal circulation, where it binds the GHRH receptor on anterior pituitary somatotropes. Ghrelin — produced principally in the stomach — binds a separate receptor (GHSR-1a) on the same somatotropes. Both signals drive pulsatile GH release. A counter- regulatory peptide, somatostatin, suppresses GH release; the net output is the characteristic rhythmic GH pulse pattern observed in healthy adults.

Released GH acts at hepatic GH receptors to induce insulin-like growth factor 1 (IGF-1) production, which mediates most of the systemic anabolic effects of GH. Negative feedback from IGF-1 and from GH itself closes the loop at the hypothalamic level. The pulsatility of release is not incidental — sustained, non-pulsatile elevation of GH is pharmacologically and clinically distinct from physiological pulsatile GH and carries a different side-effect profile.

The axis at a glance

  1. Hypothalamus releases GHRH (and somatostatin, which is inhibitory).
  2. Anterior pituitary somatotropes release GH in pulses.
  3. GH acts on the liver to produce IGF-1.
  4. IGF-1 mediates many anabolic effects of GH.
  5. Feedback from IGF-1 and GH suppresses hypothalamic GHRH.

Peptide interactions claimed in the literature

  • GHRH analogues — e.g. tesamorelin, CJC-1295. Bind GHRH receptors on somatotropes and stimulate endogenous GH release. Tesamorelin is the only GHRH analogue with FDA/EMA approval (HIV-associated lipodystrophy).
  • GH secretagogues / GHRPs — e.g. ipamorelin. Bind GHSR-1a and stimulate GH release through a different pathway. The most-studied combination in this class is GHRH-analogue + GHRP, which has been investigated for synergistic pulse amplification.
  • Lipolytic GH fragments — e.g. AOD-9604. Derived from the C-terminal region of GH, claimed to have lipolytic action without systemic IGF-1 elevation.

Evidence status

Human evidence: strongest for tesamorelin in the approved HIV-lipodystrophy indication (multiple Phase III trials). CJC-1295 and ipamorelin have small-trial human PK and GH-release data but no regulator-approved indication. AOD-9604 has human trial data in obesity contexts but failed to demonstrate meaningful clinical efficacy and was not pursued to approval.

Preclinical evidence: abundant for all GH-axis peptides in this class, dominated by rodent GH-release pharmacology and body-composition studies. Translation to human clinical outcomes is the usual constraint — see animal vs human evidence.

Critical caveat: stimulating endogenous GH release is not the same as administering recombinant GH. Effect size, pulsatility, and downstream IGF-1 levels differ. Many human studies in this class report modest, indirect endpoints (waist circumference, fat-free mass) rather than functional outcomes.

Regulatory sensitivity

Recombinant GH itself is a prescription-only medicine. GHRH analogues and GHRPs are unapproved in the UK for any indication other than tesamorelin's narrow approval elsewhere. The class is also heavily scrutinised under anti-doping rules — peptide GH secretagogues are explicitly prohibited under WADA.

Related on this site